Bolt Biotherapeutics Inc
NASDAQ:BOLT

Watchlist Manager
Bolt Biotherapeutics Inc Logo
Bolt Biotherapeutics Inc
NASDAQ:BOLT
Watchlist
Price: 7.09 USD 8.24% Market Closed
Market Cap: $13.6m

Net Margin

-821.6%
Current
Improving
by 191.9%
vs 3-y average of -1 013.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-821.6%
=
Net Income
$-42.7m
/
Revenue
$5.2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-821.6%
=
Net Income
$-42.7m
/
Revenue
$5.2m

Peer Comparison

Country Company Market Cap Net
Margin
US
Bolt Biotherapeutics Inc
NASDAQ:BOLT
13.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 92% of companies in the United States of America
Percentile
8th
Based on 15 072 companies
8th percentile
-821.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Bolt Biotherapeutics Inc
Glance View

Market Cap
13.6m USD
Industry
Biotechnology

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company is headquartered in Redwood City, California and currently employs 91 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The Company’s products include BDC-1001, BDC-2034, BDC-3042 and PD-L1 Boltbody Immune-Stimulating Antibody Conjugate (ISAC). The Company’s lead product candidate, BDC-1001, is in clinical development for the treatment of patients with HER2-expressing solid tumors, including those with HER2-low tumors. BDC-2034 is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). CEA is a well-known tumor antigen expressed in various solid tumors with significant unmet medical need. BDC-3042 is an agonist antibody targeting Dectin-2, which is an innate immune receptor found on the surface of macrophages. PD-L1 Boltbody ISAC focused on the treatment of patients with tumors that are nonresponsive or become refractory to immune checkpoint blockade.

BOLT Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-821.6%
=
Net Income
$-42.7m
/
Revenue
$5.2m
What is Bolt Biotherapeutics Inc's current Net Margin?

The current Net Margin for Bolt Biotherapeutics Inc is -821.6%, which is above its 3-year median of -1 013.5%.

How has Net Margin changed over time?

Over the last 3 years, Bolt Biotherapeutics Inc’s Net Margin has increased from -1 976.3% to -821.6%. During this period, it reached a low of -1 976.3% on Sep 30, 2022 and a high of -556.7% on Mar 31, 2024.

Back to Top